Categories: Health

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Company announcement – No. 52 / 2024

Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.

Copenhagen, Denmark, 25 December 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today reports receipt on 23 December 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholder:

As of 20 December 2024, The Capital Group Companies, Inc. held voting rights corresponding to 6.20% of the total voting rights in Zealand Pharma A/S. The Capital Group Companies notes that neither The Capital Group Companies nor any of its affiliates own shares of Zealand Pharma A/S for its own account. Rather, the shares reported in this major shareholder notification are owned by accounts under the discretionary investment management of one or more of the investment management companies described in the notification form attached.

Please see further details in the attached notification form.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand, please visit http://www.zealandpharma.com.

Contact:

Neshat Ahmadi (Investors)
Investor Relations Manager
Email: neahmadi@zealandpharma.com 

Adam Lange (Investors)
Investor Relations Officer
Email: alange@zealandpharma.com 

Anna Krassowska, PhD (Media and Investors)
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com 

GlobeNews Wire

Recent Posts

HABANOS, S.A. WELCOMES THE XXV FESTIVAL DEL HABANO WITH THE CELEBRATION OF THE 150TH ANNIVERSARY OF ROMEO Y JULIETA

The exclusive Salón de Protocolo Cubanacán hosted 1,200 guests at an event where the Romeo y…

3 hours ago

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

Major finding provides mechanistic explanation for ibezapolstat's (IBZ) selectivity in that the predicted bactericidal interaction…

3 hours ago

FOUR COUNTRIES SHORTLISTED TO HOST THE GAMES OF THE FUTURE 2027

Brazil, Serbia, South Africa, and Uzbekistan in the race to host the global phygital sports…

6 hours ago

Survey: Indian Executives Outpace Global Peers in Focus on New Technology Opportunities

BRUSSELS, Feb. 25, 2025 /PRNewswire/ -- Indian C-suite business leaders are far more focused on the…

6 hours ago

Bhandup West Embraces Healthy Sundays with Arkade Developers Happy Streets at Arkade Rare

~  In the last 5 weekends, the event has witnessed a crowd of more than…

6 hours ago

TOP 10 TRANSFORMATIONAL PERSONALITIES REVOLUTIONIZING INDIA

Unveiled by Kiteskraft Productions LLP CHANDIGARH, India, Feb. 25, 2025 /PRNewswire/ -- India's transformation is…

6 hours ago